297 related articles for article (PubMed ID: 32729347)
1. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
Phisalprapa P; Kositamongkol C; Limsrivilai J; Aniwan S; Charatcharoenwitthaya P; Pisespongsa P; Kitiyakara T; Treepongkaruna S; Chaiyakunapruk N
J Med Econ; 2020 Nov; 23(11):1302-1310. PubMed ID: 32729347
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
3. Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease.
Catt H; Bodger K; Kirkham JJ; Hughes DA
Pharmacoeconomics; 2019 Dec; 37(12):1509-1523. PubMed ID: 31372948
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
Aliyev ER; Hay JW; Hwang C
Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
[TBL] [Abstract][Full Text] [Related]
5. A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia.
Brodszky V; Rencz F; Péntek M; Baji P; Lakatos PL; Gulácsi L
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):119-25. PubMed ID: 26162458
[TBL] [Abstract][Full Text] [Related]
6. The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era.
Vasudevan A; Ip F; Liew D; van Langenberg DR
Inflamm Bowel Dis; 2020 Feb; 26(3):369-379. PubMed ID: 31532479
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China.
Chen H; Shi J; Pan Y; Zhang Z; Fang H; Chen Y; Chen W; Cao Q
Adv Ther; 2020 Jan; 37(1):431-449. PubMed ID: 31797196
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn's Disease using Real-World Data.
Pillai N; Lupatsch JE; Dusheiko M; Schwenkglenks M; Maillard M; Sutherland CS; Pittet VEH;
J Crohns Colitis; 2020 May; 14(4):490-500. PubMed ID: 31630164
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis.
Aungsumart S; Apiwattanakul M
PLoS One; 2020; 15(2):e0229028. PubMed ID: 32050011
[TBL] [Abstract][Full Text] [Related]
11. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn's disease in China.
Shi JH; Luo L; Chen XL; Pan YP; Zhang Z; Fang H; Chen Y; Chen WD; Cao Q
World J Gastroenterol; 2020 Nov; 26(41):6455-6474. PubMed ID: 33244205
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis.
Aungsumart S; Turongkaravee S; Youngkong S; Apiwattanakul M; Thakkinstian A; Chaikledkaew U
BMC Health Serv Res; 2023 Oct; 23(1):1096. PubMed ID: 37833729
[TBL] [Abstract][Full Text] [Related]
13. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.
Saito S; Shimizu U; Nan Z; Mandai N; Yokoyama J; Terajima K; Akazawa K
J Crohns Colitis; 2013 Mar; 7(2):167-74. PubMed ID: 22626508
[TBL] [Abstract][Full Text] [Related]
14. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
[TBL] [Abstract][Full Text] [Related]
15. Cost-Utility Analysis of Biologic Disease-Modifying Antirheumatic Drugs for Patients With Psoriatic Arthritis in Thailand.
Dilokthornsakul P; Sawangjit R; Osiri M; Chiowchanwisawakit P; Louthrenoo W; Permsuwan U
Value Health Reg Issues; 2023 Mar; 34():40-47. PubMed ID: 36469988
[TBL] [Abstract][Full Text] [Related]
16. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.
Jha A; Upton A; Dunlop WC; Akehurst R
Adv Ther; 2015 Aug; 32(8):742-56. PubMed ID: 26343027
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.
Tang DH; Armstrong EP; Lee JK
Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand.
Kittiratchakool N; Kulpokin D; Chanjam C; Vilaiyuk S; Charuvanij S; Phongsamart G; Khaosut P; Tanya M; Nanagara R; Nantapaisarn S; Leelahavarong P
BMJ Open; 2020 Sep; 10(9):e037588. PubMed ID: 32933962
[TBL] [Abstract][Full Text] [Related]
19. The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
Severs M; Oldenburg B; van Bodegraven AA; Siersema PD; Mangen MJ;
J Crohns Colitis; 2017 Mar; 11(3):289-296. PubMed ID: 27571772
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients.
Phisalprapa P; Supakankunti S; Charatcharoenwitthaya P; Apisarnthanarak P; Charoensak A; Washirasaksiri C; Srivanichakorn W; Chaiyakunapruk N
Medicine (Baltimore); 2017 Apr; 96(17):e6585. PubMed ID: 28445256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
